Arvind N. Dasari, MD, MS

Peer-Reviewed Articles

1. Folkert, I, Mehran, RJ, Sun, R, Morris, VK, Overman, MJ, Kee, BK, Antonoff, MB, Tzeng, CW, Dasari, NV, Tran Cao, HS, Parseghian, C, Vilar Sanchez, E, Willis, JA, Newhook, TE, Hofstetter, WL, Kopetz, S, Vauthey, JN, Chun, YS. Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA). Annals of surgical oncology 33(4):2899-2907, 2026. e-Pub 2026. PMID: 41369813.
2. Guo, J, Lewis, KA, Prakash, L, Bhosale, PR, Morani, A, Katz, MH, Tzeng, CD, Ikoma, N, Snyder, RA, Kim, M, Chandrasekharan, C, Dasari, NV, Yao, JC, Lee, JE, Maxwell, JE, Halperin, DM. Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. Current Oncology 33(2), 2026. e-Pub 2026. PMID: 41744875.
3. Bent, AH, Dasari, NV, Joshua Smith, J. Are We There Yet? The Telltale Trail of ctDNA in Rectal Cancer. Clinical Cancer Research 31(24):5117-5119, 2025. e-Pub 2025. PMID: 41114665.
4. Pellatt, AJ, Barnett, RM, Gnerre, S, Edwards, K, Willis, JA, Overmann, MJ, Raghav, KS, Parseghian, C, Dasari, NV, Morelli, MP, Bent, AH, Eluri, M, Hornstein, N, Drusbosky, L, Kopetz, S, Morris, VK. Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach. BMC cancer 25(1), 2025. e-Pub 2025. PMID: 40696295.
5. Morris, VK, Parseghian, C, Bahrambeigi, V, Abdelfattah, N, Xiao, L, Agrawal, A, Lin, K, Raghav, KS, Wolff, RA, Dasari, NV, Huey, RW, Kee, BK, Overman, MJ, Willis, JA, Le, PH, Escano, M, Baig, YC, Pan, K, Menter, DG, Tam, AL, Foo, WC, Shen, L, Lee, HM, Gallup, T, Margain, C, Gallup, D, Rajapakshe, K, Guerrero, PA, Wang, J, Corcoran, RB, Maitra, A, Yun, K, Kopetz, S. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer. Cancer cell 43(11):2106-2118.e3, 2025. e-Pub 2025. PMID: 40882637.
6. Zhou, X, Toms, A, Morton, D, Wang, X, Taylor, A, Dasari, NV, Gupta, N, Chien, C. Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. Journal of Clinical Pharmacology 65(11):1411-1419, 2025. e-Pub 2025. PMID: 40485075.
7. Dasari, NV, Eng, C, Lonardi, S, Garcia-Carbonero, R, Masuishi, T, Cremolini, C, Ghiringhelli, F, Hubbard, J, Bekaii-Saab, T, Jones, J, Xu, R, Shen, L, Xu, JM, Bai, YX, Deng, Y, Yuan, Y, Wei, W, Lin, J, Chen, L, Yang, Z, Schelman, WR, Qin, SK, Li, J. Fruquintinib in less pretreated patients. European Journal of Cancer 227, 2025. e-Pub 2025. PMID: 40795524.
8. Garcia-Carbonero, R, Elez, E, García-Alfonso, P, Cubillo, A, Lopez, R, Jiménez-Fonseca, P, Limon Miron, ML, Dasari, NV, Lonardi, S, Zhu, H, Chen, L, Yang, Z, Schelman, WR, Tabernero, J. Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain. ESMO Gastrointestinal Oncology 9, 2025. e-Pub 2025. PMID: 41647991.
9. Alvarez, JA, Zambare, W, George, M, Garcia, R, Gallagher, P, Kitchens, C, Bercz, A, Kim, MJ, Romesser, P, Cercek, A, García-Aguilar, J, Sanoff, HK, George, TJ, Hong, TS, Yothers, G, Philip, PA, Al Baghdadi, T, Alese, OB, Shergill, A, O'Reilly, EM, Meyerhardt, JA, Horvat, N, Dasari, NV, Hall, WA, Shi, Q, Schrag, D, Smith, JJ. Utilizing Patient Input in Rectal Cancer Trial Design. Journal of the National Cancer Institute 117(7):1421-1428, 2025. e-Pub 2025. PMID: 40108482.
10. Zhou, X, Yang, X, Grinshpun, B, Taylor, A, Strong, L, Dasari, NV, Wang-Gillam, A, Li, J, Xu, R, Gupta, N, Chien, C. Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer. Journal of Clinical Pharmacology 65(7):873-884, 2025. e-Pub 2025. PMID: 39969131.
11. Pellatt, AJ, Bent, AH, Hornstein, N, Parseghian, C, Huey, RW, Raghav, KS, Morris, VK, Overman, MJ, Morelli, P, Willis, JA, Le, PH, Shen, JY, Kee, BK, Eluri, M, Higbie, V, Alfaro-Munoz, KD, Aziz, KE, Kell, R, Sun, R, Kopetz, S, Dasari, NV. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40669021.
12. Dasari, NV, Wallace, K, Halperin, DM, Maxwell, JE, Kunz, PL, Singh, S, Chasen, B, Yao, JC. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open 8(6), 2025. e-Pub 2025. PMID: 40553474.
13. Sammour, T, Peacock, O, Bednarski, BK, Dasari, NV, Das, P, Johnson, B, Smith, GL, Chang, GJ, Skibber, JM, You, YN. Prospective longitudinal trajectory of cancer survivorship among patients with recurrent rectal cancer. Colorectal Disease 27(5), 2025. e-Pub 2025. PMID: 40371878.
14. Raghav, KS, Guthrie, KA, Tan, BR, Denlinger, CS, Fakih, MG, Overman, MJ, Dasari, NV, Corum, LR, Hicks, LG, Patel, MS, Esparaz, BT, Kazmi, SM, Alluri, N, Colby, S, Gholami, S, Gold, PJ, Chiorean, EG, Kopetz, S, Hochster, HS, Philip, PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613). Journal of Clinical Oncology 43(11):1348-1357, 2025. e-Pub 2025. PMID: 39761503.
15. Sobrero, AF, Dasari, NV, Aquino, J, Lonardi, S, Garcia-Carbonero, R, Elez, E, Yoshino, T, Yao, JC, García-Alfonso, P, Kocsis, J, Gracián, AC, Sartore-Bianchi, A, Satoh, T, Randrian, V, Tomasek, J, Chong, G, Price, T, Yu, Z, Geiger, A, Chen, L, Yang, Z, Schelman, WR, Kania, M, Tabernero, J, Eng, C. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer. European Journal of Cancer 218, 2025. e-Pub 2025. PMID: 39952149.
16. Eng, C, Dasari, NV, Lonardi, S, Garcia-Carbonero, R, Elez, E, Yoshino, T, Sobrero, AF, Yao, JC, García-Alfonso, P, Kocsis, J, Gracián, AC, Sartore-Bianchi, A, Satoh, T, Randrian, V, Tomasek, J, Chong, G, Yang, Z, Guevara, F, Schelman, WR, Pallai, R, Tabernero, J. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40163688.
17. Stintzing, S, Tabernero, J, Satoh, T, Dasari, NV, Lonardi, S, Eng, C, Garcia-Carbonero, R, Elez, E, Yoshino, T, Sobrero, AF, Yao, JC, Kasper, S, Arnold, D, Basic, E, Granold, M, Petschulies, M, Wu, L, Chung, YC, Chen, L, Yang, Z, Van Cutsem, E. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care. ESMO Open 10(3), 2025. e-Pub 2025. PMID: 39985889.
18. Rajdev, L, King, G, Lieu, C, Cohen, S, Pant, S, Uboha, NA, Deming, DA, Malla, M, Kasi, A, Klute, K, Spencer, K, Dasari, NV, Morris, VK, Botta, G, Lowy, AM, O'Hara, MH, Eads, JR, King, DA, Shah, MA, Hong, TS, Parikh, AR, Klempner, SJ, Jabbour, SK, Chawla, A, Molena, D, George, TJ, Gibson, MK, Allegra, C, Goodman, KA, Eng, C, Philip, PA. Incorporating Circulating Tumor DNA Testing Into Clinical Trials. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40048671.
19. Chan, JA, Geyer, S, Zemla, TJ, Knopp, MV, Behr, SC, Pulsipher, S, Ou, FS, Dueck, A, Acoba, J, Shergill, A, Wolin, EM, Halfdanarson, TR, Konda, B, Trikalinos, NA, Tawfik, B, Raj, N, Shaheen, S, Vijayvergia, N, Dasari, NV, Strosberg, JR, Kohn, E, Kulke, MH, O'Reilly, EM, Meyerhardt, JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine 392(7):653-665, 2025. e-Pub 2025. PMID: 39282913.
20. White, MG, Zeineddine, MA, Fallon, EA, Zeineddine, F, Dansby, J, Chowdhury, S, Hornstein, N, Yousef, A, Yousef, M, Bhutiani, N, Gu, Y, Kee, BK, Dasari, NV, Overman, MJ, Raghav, KS, Kopetz, S, Uppal, A, Taggart, MW, Newhook, TE, Fournier, KF, Helmink, BA, Drusbosky, L, Shen, JY. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clinical Cancer Research 31(3):551-560, 2025. e-Pub 2025. PMID: 39679931.
21. Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers:1-13, 2025. e-Pub 2025. PMID: 39761813.
22. Dasari, NV, Lonardi, S, MacLeod, B, McPeak, S, Tabernero, J, Eng, C. Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer. Future Oncology 21(3):281-292, 2025. e-Pub 2025. PMID: 39614128.
23. Bhutiani, N, Peacock, O, Uppal, A, Hu, C, Bednarski, BK, Taggart, MW, Dasari, NV, Morris, VK, Kaur, H, Kopetz, S, Holliday, EB, Das, P, You, YN, Chang, GJ. The prognostic impact of tumor deposits in colorectal cancer. Cancer 130(23):4052-4060, 2024. e-Pub 2024. PMID: 39306694.
24. Alvarez, JA, Shi, Q, Dasari, NV, Garcia-Aguilar, J, Sanoff, HK, George, TJ, Hong, TS, Yothers, G, Philip, PA, Nelson, GD, Al Baghdadi, T, Alese, OB, Zambare, W, Omer, D, Verheij, FS, Bercz, A, Kim, MJ, Buckley, J, Williams, H, George, M, Garcia, R, Gallagher, P, O’Reilly, EM, Meyerhardt, JA, Crawley, J, Shergill, A, Horvat, N, Romesser, P, Hall, WA, Joshua Smith, J. Alliance A022104/NRG-GI010. BMC cancer 24(1), 2024. e-Pub 2024. PMID: 39060961.
25. Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
26. Chang, E, Wong, FC, Chasen, B, Erwin, WD, Das, P, Holliday, EB, Koong, A, Ludmir, EB, Minsky, B, Noticewala, SS, Smith, GL, Taniguchi, C, Rodriguez, MJ, Beddar, S, Martin, RM, Niedzielski, JS, Sawakuchi, GO, Schueler, E, Perles, LA, Xiao, L, Szklaruk, J, Park, PC, Dasari, NV, Kaseb, A, Kee, BK, Lee, SS, Overman, MJ, Willis, JA, Wolff, RA, Tzeng, CD, Vauthey, JN, Koay, EJ. Phase i trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectrum 8(3), 2024. e-Pub 2024. PMID: 38730548.
27. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer Journal for Clinicians 74(4):359-367, 2024. e-Pub 2024. PMID: 38685134.
28. Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A. Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila) 17(7):335-342, 2024. e-Pub 2024. PMID: 38662083.
29. DiBrito SR, Manisundaram N, Kim Y, Peacock O, Hu CY, Bednarski B, You YN, Uppal A, Tillman M, Konishi T, Kaur H, Palmquist S, Holliday E, Dasari A, Chang GJ. Perioperative and oncological outcomes following robotic en bloc multivisceral resection for colorectal cancer. Colorectal Dis 26(5):949-957, 2024. e-Pub 2024. PMID: 38576073.
30. Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel) 16(4), 2024. e-Pub 2024. PMID: 38398128.
31. Higbie, V, Shah, P, Bent, AH, Dasari, NV, Huey, RW, Johnson, B, Kee, BK, Kopetz, S, Lee, MS, Ludford, K, Morelli, MP, Morris, VK, Parseghian, C, Raghav, KS, Shen, JY, Willis, JA, Wolff, RA, Overman, MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
32. Lieu, C, Yu, G, Kopetz, S, Puhalla, S, Lucas, PC, Sahin, IH, Deming, DA, Philip, PA, Hong, TS, Rojas-Khalil, Y, Loree, JM, Wolmark, N, Yothers, G, George, TJ, Dasari, NV. NRG-GI008. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
33. Maddalena, G, Pellatt, AJ, Eluri, M, Parseghian, C, Aziz, KE, Alfaro, KD, Kell, R, Bent, AH, Huey, RW, Uppal, A, Konishi, T, Overman, MJ, Morelli, MP, Willis, JA, Shen, JY, Raghav, KS, Newhook, TE, Morris, VK, Dasari, NV, Kopetz, S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC). Journal of Clinical Oncology 42(3_suppl):27, 2024. e-Pub 2024.
34. Pellatt, AJ, Maddalena, G, Bent, AH, Parseghian, C, Huey, RW, Raghav, KS, Morris, VK, Overman, MJ, Morelli, MP, Willis, JA, Le, PH, Shen, JY, Alfaro, KD, Aziz, KE, Kell, R, Sun, R, Kopetz, S, Dasari, NV. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
35. Stintzing, S, Tabernero, J, Satoh, T, Dasari, NV, Lonardi, S, Eng, C, Garcia-Carbonero, R, Elez, E, Yoshino, T, Sobrero, AF, Yao, JC, Kasper, S, Arnold, D, Basic, E, Granold, M, Petschulies, M, Wu, L, Chen, L, Yang, Z, Van Cutsem, E. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 42(3_suppl):116, 2024. e-Pub 2024.
36. Paly, VF, Dasari, NV, Hubbard, J, Bekaii-Saab, T, Padukkavidana, T, Hernandez, L. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the us. Journal of Comparative Effectiveness Research 13(8), 2024. e-Pub 2024. PMID: 38976346.
37. Cordero-Hernandez IS, Ross AC, Dasari A, Halperin DM, Chasen B, Yao JC. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer 31(4), 2024. e-Pub 2024. PMID: 38329269.
38. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
39. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
40. Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L, Meyer JE, Monzon J, Saltz L, Schrag D, Smith JJ, Zell JA, Das P, Force NCI. NCI Rectal-Anal Task Force Consensus Recommendations for Design of Clinical Trials in Rectal Cancer. Journal of the National Cancer Institute 115(12):1457-1464, 2023. e-Pub 2023. PMID: 37535679.
41. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of Clinical Oncology 41(32):5049-5067, 2023. e-Pub 2023. PMID: 37774329.
42. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
43. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst 115(8):994-997, 2023. e-Pub 2023. PMID: 37202363.
44. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-related cancer 30(8), 2023. e-Pub 2023. PMID: 37184955.
45. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, Investigators FS. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402(10395):41-53, 2023. e-Pub 2023. PMID: 37331369.
46. Dasari A, Hamilton EP, Falchook GS, Wang JS, Li D, Sung MW, Chien C, Nanda S, Tucci C, Hahka-Kemppinen M, Paulson AS. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Investigational New Drugs 41(3):421-430, 2023. e-Pub 2023. PMID: 37074571.
47. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Annals of surgery 277(5):813-820, 2023. e-Pub 2022. PMID: 35797554.
48. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
49. Wong WG, Dasari A, Shen C. Association of Surgery and Chemotherapy in Stage IV Gastroenteropancreatic Neuroendocrine Carcinoma. Journal of Surgical Research 283:407-415, 2023. e-Pub 2023. PMID: 36434836.
50. Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. European Journal of Cancer 182:43-52, 2023. e-Pub 2023. PMID: 36738541.
51. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
52. Monlezun DJ, Badalamenti A, Javaid A, Marmagkiolis K, Honan K, Kim JW, Patel R, Akhanti B, Halperin D, Dasari A, Koutroumpakis E, Kim P, Lopez-Mattei J, Yusuf SW, Cilingiroglu M, Mamas MA, Gregoric I, Yao J, Hassan S, Iliescu C. Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the "forgotten pulmonic valve". Frontiers in Cardiovascular Medicine 9, 2023. e-Pub 2023. PMID: 36843627.
53. Sobrero, A, Dasari, NV, Lonardi, S, Garcia-Carbonero, R, Elez, E, Yoshino, T, Yao, JC, Garcia-Alfonso, P, Kocsis, J, Cubillo, A, Sartore-Bianchi, A, Satoh, T, Randrian, V, Tomasek, J, Chong, G, Yang, Z, Schelman, WR, Kania, M, Tabernero, J, Eng, C. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. Journal of Clinical Oncology 41(4):67, 2023. e-Pub 2023.
54. Honan KA, Hassan S, Deswal A, Herrmann J, Song J, Monlezun D, Halperin D, Mahvash A, Dasari A, Koutroumpakis E, Akay M, Balanescu DV, de Armas IS, Patel M, Nathan S, Kar B, Marmagkiolis K, Lopez-Mattei J, Patel J, Gregoric I, Yao J, Iliescu CA. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Frontiers in Cardiovascular Medicine 9, 2023. e-Pub 2023. PMID: 36712267.
55. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
56. Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park) 36(10):604-608, 2022. e-Pub 2022. PMID: 36260786.
57. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Network Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
58. Peacock O, Manisundaram N, Dibrito SR, Kim Y, Hu CY, Bednarski BK, Konishi T, Stanietzky N, Vikram R, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer after Total Neoadjuvant Therapy (TNT). Annals of surgery 10(4):654-664, 2022. e-Pub 2022. PMID: 35837891.
59. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
60. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal for immunotherapy of cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
61. Wong W, Perez Holguin RA, Olecki EJ, Stahl KA, Dixon M, Peng J, Dasari A, Shen C. Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors : Minimally Invasive Surgery for SBNETs. Journal of Gastrointestinal Surgery 103(2):125-38, 2022. e-Pub 2022. PMID: 35132564.
62. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncology 3(10):1335-1342, 2022. e-Pub 2022. PMID: 35389428.
63. Dasari A, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Journal of Clinical Oncology(40):TPS3643-TPS3643, 2022. e-Pub 2022.
64. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum. Obstetric Medicine 15(2):118-124, 2022. e-Pub 2022. PMID: 35845232.
65. Mohamed A, Asa SL, McCormick T, Al-Shakhshir H, Dasari A, Mauricio R, Salem I, Ocuin LM, Bajor D, Lee RT, Selfridge JE, Kardan A, Lee Z, Avril N, Kopp S, Winter JM, Hardacre JM, Ammori JB, Ghannoum MA. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology 44(5):2015-2028, 2022. e-Pub 2022. PMID: 35678665.
66. Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. Annals of surgical oncology 29(4):2539-2548, 2022. e-Pub 2022. PMID: 34787737.
67. Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist 27(4):299-306, 2022. e-Pub 2022. PMID: 35380711.
68. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
69. Erstad, D J, Dasari, A, Taggart, M W, Kaur, H, Konishi, T, Bednarski, B K, Chang, G J. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas. Annals of surgical oncology 29(4):2549-2549, 2022. e-Pub 2022. PMID: 34787737.
70. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical colorectal cancer 21(1):e28-e37, 2022. e-Pub 2022. PMID: 34794903.
71. Villarreal O, Zeineddine FA, Chacko R, Parseghian CM, Johnson B, Willis J, Lee MS, Morris VK, Dasari A, Pratap K, Raghav S, Overman MJ, You Y, Wang Y, Maru DM, YC Shen JP, Kopetz S. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. Journal of Clinical Oncology 40(4):22-22, 2022. e-Pub 2022.
72. Nusrat M, Syed MA, Katkhuda R, Parra ER, Wistuba II, Kong P, Koehne A, Dasari A, Overman MJ, Menter D, Kopetz S. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. Journal of Clinical Oncology 40(4):154-154, 2022. e-Pub 2022.
73. You YN, Dasari A, Chang GJ. Report from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021. Diseases of the colon and rectum 65(1):8-10, 2022. e-Pub 2022. PMID: 34784317.
74. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2022. PMID: 33434908.
75. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
76. Dasari A, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Halil Sahin IH, Deming DA, Philip PA, Hong TS, Wolmark N, Yothers G, George TJ, Lieu CH. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). Journal of Clinical Oncology 40(4). e-Pub 2022.
77. Dasari A, Abdelrahim M, Acoba JD, Alluri KC, Dragovivh T, Ali Kazmi SM, Musher BL, Sun R, Wong L, You Y, Zaiden RA, Kopetz S. Minimal residual disease assessment in colorectal cancer (MiRDA-C). Journal of Clinical Oncology 40(4). e-Pub 2022.
78. Soares HP, Guthrie KA, Ahmad SA, Washington MK, Ramnaraign BH, Raj NP, Seigel C, Bellasea S, Chiorean E, Dasari A, Strosberg JR, Eng C, Philip PA. Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. Journal of Clinical Oncology 40 40. e-Pub 2022.
79. Dasari A, Hubbard JM, Eng C, Yeckes-Rodin H, Ukrainskyj SM, Yang Z, Schelman WR, Kania MK, Bekaii-Saab TS. Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer. Journal of Clinical Oncology 40(4):93-93, 2022. e-Pub 2022.
80. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2022. PMID: 33434908.
81. Strosberg JR, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, Dasari A, Philip P, Soulen MC. Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?. Journal of Nuclear Medicine 62(12):1669-71, 2021. e-Pub 2021. PMID: 34556527.
82. Fujii Y, Tzeng CW, Chiang YJ, Halperin DM, Dasari A, Kim MP, Katz MHG, Lee JE, Ikoma N. Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. Journal of Surgical Research 268:419-431, 2021. e-Pub 2021. PMID: 34416414.
83. Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng C. Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Supportive Care in Cancer 29(12):7351-7354, 2021. e-Pub 2021. PMID: 34050401.
84. Shirali AS, Pieterman CRC, Lewis MA, Hyde SM, Makawita S, Dasari A, Thosani N, Ikoma N, McCutcheon IE, Waguespack SG, Perrier ND. It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. CA Cancer Journal for Clinicians 71(5):369-380, 2021. e-Pub 2021. PMID: 34061974.
85. Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 17(24):3151-3162, 2021. e-Pub 2021. PMID: 33993740.
86. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. International Journal of Infectious Diseases 108:419-421, 2021. e-Pub 2021. PMID: 34087489.
87. MacFarlane AW, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunology, Immunotherapy 70(7):1893-1906, 2021. e-Pub 2021. PMID: 33398390.
88. Arhin ND, Shen C, Bailey CE, Matsuoka LK, Hawkins AT, Holowatyj AN, Ciombor KK, Hopkins MB, Geiger TM, Kam AE, Roth MT, Lebeck Lee CM, Lapelusa M, Dasari A, Eng C. Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer medicine 10(13):4269-4281, 2021. e-Pub 2021. PMID: 34132476.
89. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical colorectal cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
90. Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33916960.
91. Malakorn S, Ouchi A, Hu CY, Sandhu L, Dasari A, You YN, Kopetz ES, Ellis LM, Chang GJ. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clinical colorectal cancer 20(1):e53-e60, 2021. e-Pub 2021. PMID: 33004292.
92. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2021. PMID: 32960478.
93. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precision Oncology 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
94. Kawaguchi Y, Newhook TE, Tran Cao HS, Tzeng CD, Chun YS, Aloia TA, Dasari A, Kopetz S, Vauthey JN. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. Journal of Gastrointestinal Surgery 25(1):186-194, 2021. e-Pub 2021. PMID: 33205306.
95. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
96. Peacock O, Limvorapitak T, Bednarski BK, Kaur H, Taggart MW, Dasari A, Holliday EB, Minsky BD, You YN, Chang GJ. Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective. Colorectal Dis 22(12):2049-2056, 2020. e-Pub 2020. PMID: 32892473.
97. Peacock O, Limvorapitak T, Hu CY, Bednarski BK, Tillman MM, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Robotic rectal cancer surgery: comparative study of the impact of obesity on early outcomes. Br J Surg 107(12):1552-1557, 2020. e-Pub 2020. PMID: 32996597.
98. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res 20(5):1-5, 2020. e-Pub 2020. PMID: 31448649.
99. Unger JM, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectrum 4(4), 2020. e-Pub 2020. PMID: 32704619.
100. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 49(6):723-728, 2020. e-Pub 2020. PMID: 32433264.
101. Avila S, Chang GJ, Dasari NA, Smani DA, Das P, Herman JM, Koay E, Koong A, Krishnan S, Minsky BD, Smith GL, Taniguchi C, Taggart MW, Kaur H, Holliday EB. Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer 19(2):116-122, 2020. e-Pub 2020. PMID: 32173279.
102. Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 122(9):1309-1314, 2020. e-Pub 2020. PMID: 32152503.
103. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
104. Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 126(4):792-799, 2020. e-Pub 2020. PMID: 31714595.
105. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 25(47):6857, 2019. e-Pub 2019. PMID: 31885426.
106. Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 30(11):1847, 2019. e-Pub 2019. PMID: 31407007.
107. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol 5(10):e191870, 2019. e-Pub 2019. PMID: 31415071.
108. Malakorn S, Yang Y, Bednarski BK, Kaur H, You YN, Holliday EB, Dasari A, Skibber JM, Rodriguez-Bigas MA, Chang GJ. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?. Dis Colon Rectum 62(10):1158-1166, 2019. e-Pub 2019. PMID: 31490825.
109. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
110. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 24(8):1056-1065, 2019. e-Pub 2019. PMID: 30606883.
111. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist 24(8):1066-1075, 2019. e-Pub 2019. PMID: 30610008.
112. Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. JCO Clin Cancer Inform 3:1-10, 2019. e-Pub 2019. PMID: 31283354.
113. Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas 48(4):510-513, 2019. e-Pub 2019. PMID: 30946241.
114. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 30(3):495, 2019. e-Pub 2019. PMID: 29982323.
115. Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386, 2019. e-Pub 2019. PMID: 30768575.
116. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
117. Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 48(10):1373-1379, 2019. e-Pub 2019. PMID: 31688604.
118. Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 33015522.
119. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
120. Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist 23(12):1409-e140, 2018. e-Pub 2018. PMID: 30139840.
121. Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 8(1):16863, 2018. e-Pub 2018. PMID: 30442902.
122. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78(18):5398-5407, 2018. e-Pub 2018. PMID: 30042150.
123. Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 36(8):1005-1013, 2018. e-Pub 2018. PMID: 29682693.
124. Husnain M, Park W, Ramos JC, Johnson TE, Chan J, Dasari A, Mudad R, Hosein PJ. Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. J Immunother Cancer 6(1):1-5, 2018. e-Pub 2018. PMID: 29986769.
125. Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol 25(6):1709-1715, 2018. e-Pub 2018. PMID: 29626307.
126. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
127. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 124(4):807-815, 2018. e-Pub 2018. PMID: 29211313.
128. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
129. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12):1451-1462, 2017. e-Pub 2017. PMID: 28642335.
130. Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
131. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335-1342, 2017. e-Pub 2017. PMID: 28448665.
132. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
133. Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. (*Both authors contributed equally). Ann Oncol 28(7):1582-1589, 2017. e-Pub 2017. PMID: 28444105.
134. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
135. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
136. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery 161(3):753-759, 2017. e-Pub 2017. PMID: 27816207.
137. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21(1):155-163, 2017. e-Pub 2017. PMID: 27634306.
138. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(5):e0173345, 2017. e-Pub 2017. PMID: 28267766.
139. Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, Kim M, Fleming JB, Katz MH, Lee JE. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. J Gastrointest Surg 20(12):1966-1974, 2016. e-Pub 2016. PMID: 27714644.
140. Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer (*Both authors contributed equally). J Clin Pharmacol 56(8):966-73, 2016. e-Pub 2016. PMID: 26632033.
141. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
142. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2016. PMID: 26810202.
143. Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 3(2):175-189, 2016. e-Pub 2016. PMID: 27347369.
144. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist 21(3):308-313, 2016. e-Pub 2016. PMID: 26911407.
145. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032, 2015. e-Pub 2015. PMID: 26460303.
146. Choi I, Dasari A, Kim NH, Campbell KH. Effects of prolonged exposure of mouse embryos to elevated temperatures on embryonic developmental competence. Reprod Biomed Online 31(2):171-9, 2015. e-Pub 2015. PMID: 26093856.
147. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and actreotide in advanced well differentiated neuroendocrine tumors. Endocr Relat Cancer 22(15):0002, 2015. e-Pub 2015. PMID: 25900182.
148. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
149. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A phase I dosing finding study in patients with advanced solid malignancies of the oral y-secretase inhibitor PF-03084014. Clin Cancer Res 21(1):60-7, 2015. e-Pub 2015. PMID: 25231399.
150. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
151. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32(4):739-45, 2014. e-Pub 2014. PMID: 24668033.
152. Rogers JE, Ohinata A, Dasari A, Eng C. Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer 13(1):e1-e4, 2014. e-Pub 2014. PMID: 24342822.
153. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. (*Both authors contributed equally). Invest New Drugs 31(2):345-54, 2013. e-Pub 2013. PMID: 22615057.
154. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 31(1):115-25, 2013. e-Pub 2013. PMID: 22415798.
155. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med 1(2):207-17, 2012. e-Pub 2012. PMID: 23342270.
156. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. J Clin Oncol 30(19):2348-53, 2012. e-Pub 2012. PMID: 22529266.
157. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH+ tumor-initiating cells that exhibit a gain in notch1 gene copy number have enhanced sensitivity to a γ-secretase inhibitor + irinotecan in colorectal cancer (CRC). Mol Oncol 6(3):370-81, 2012. e-Pub 2012. PMID: 22521243.
158. Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3'UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 18(9):2704-14, 2012. e-Pub 2012. PMID: 22553375.
159. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66(22):10805-14, 2006. e-Pub 2006. PMID: 17108117.

Invited Articles

1. Mohamed A, Asa SL, McCormick T, Al- Shakhshit H, Dasari A, Mauricio R, Salem I, Ocuin LM, Bajor D, Lee RT, J, Selfridge, Kardan A, Lee Z, Avril N, Kopp S, Winter JM, Hardacre J, Ammori JB, Ghannoum MA. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular biology(3):1335-1342, 2022. e-Pub 2022.
2. Fang L, Dasari A, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 33(3):e12943, 2021. e-Pub 2021.
3. Vijayvergia N, Dasari A. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. Curr Treat Options Oncol 21(12):1-15, 2020. e-Pub 2020. PMID: 33029680.
4. Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer 28(10):4589-4612, 2020. e-Pub 2020. PMID: 32533435.
5. George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 125(16):2732-2746, 2019. e-Pub 2019. PMID: 31017664.
6. Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett 17(5):4126-4132, 2019. e-Pub 2019. PMID: 30944605.
7. Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart 103(19):1488-1495, 2017. e-Pub 2017. PMID: 28596302.
8. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. e-Pub 2016. PMID: 27295529.
9. Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 12(3):313-21, 2016. e-Pub 2016. PMID: 26759064.
10. Dasari A, Yao J. Initial treatment of well differentiated neuroendocrine tumors. Oncology (Williston Park) 28(11):945-7, 2014. e-Pub 2014. PMID: 25741544.
11. Arcaroli JJ, Dasari A, Messersmith WA, Jimeno A. Gamma secretase inhibitors in solid tumor malignancies. Drugs of the Future 36(9):677, 2011. e-Pub 2011.
12. Dasari A, Messersmith WA. Are additional clinical trials of adjuvant Bevacizumab therapy indicated in colon cancer?. Current Colorectal Cancer Reports 7(3), 2011. e-Pub 2011.
13. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park) 24(14):1329-34, 2010. e-Pub 2010. PMID: 21294478.
14. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 16(15):3811-8, 2010. e-Pub 2010. PMID: 20554751.

Review Articles

1. Yanes R, Saridogan T, Gorantla V, Overacre A, Hsieh RW, Celebrezze J, Magge T, Singhi M, Saeed A, Zureikat AH, Dasari AN, Sahin IH. Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer. Technol Cancer Res Treat 24:15330338251317094, 2025. e-Pub 2025. PMID: 39865921.
2. Sahin, IH, Yanes, R, Saridogan, T, Holder-Murray, J, Dasari, NV. The Role of Circulating Tumor DNA for Management of Patients with Rectal Cancer. Cancer Journal (United States) 30(4):290-296, 2024. e-Pub 2024. PMID: 39042781.
3. Loree, JM, Dasari, NV, Willis, JA, Gothwal, H, Shaheed, M, Singh, K, Shaheed, H, Mangal, R, Gothwal, S, Pant, A, Overman, MJ, Kopetz, S, Raghav, KS. Racial/ethnic representation and disparities in preclinical cancer models. Journal of Clinical Oncology 42:1601, 2024. e-Pub 2024.
4. Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rodel C, Dasari A, Yoshino T. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nature Reviews Gastroenterology and Hepatology 21(6):444-455, 2024. e-Pub 2024. PMID: 38485756.
5. Pellatt, AJ, Maddalena, G, Eluri, M, Parseghian, C, Aziz, KE, Alfaro, KD, Kell, R, Bent, AH, Huey, RW, Uppal, A, Konishi, T, Overman, MJ, Morelli, MP, Willis, JA, Shen, JY, Raghav, KS, Newhook, TE, Morris, VK, Dasari, NV, Kopetz, S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease. Journal of Clinical Oncology 42:196, 2024. e-Pub 2024.
6. Chakrabarti, S, Cohen, S, Tin, A, Dangl, A, Aushev, VN, Tejani, MA, Chandana, SR, Malla, M, Landmann, RG, Sharma, VR, Botta, G, Nagarajan, A, Azzi, G, Cho, M, Dayyani, F, Hanna, D, Jurdi, A, Liu, MC, Dasari, NV, Kasi, PM. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery. Journal of Clinical Oncology 42:212, 2024. e-Pub 2024.
7. Uppal, A, Bhutiani, N, Shen, JY, Alfaro, KD, Kell, R, Yousef, M, Yousef, A, Konishi, T, Holliday, EB, Morris, VK, Dasari, NV, Willis, JA, Newhook, TE, Bednarski, BK, You, YN, Peacock, O, Messick, C, Das, P, Chang, GJ, Kopetz, S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer. Journal of Clinical Oncology 42:205, 2024. e-Pub 2024.
8. Bhamidipati, D, Haro-Silerio, JI, Ileana Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Johnson, A, Lee, MS, Dasari, NV, Raghav, KS, Morris, VK, Overman, MJ, Kopetz, S, Meric-Bernstam, F, Yap, TA. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. Journal of Clinical Oncology 42:134, 2024. e-Pub 2024.
9. Maddalena, G, van der Pol, Y, Rivers, Z, Dasari, NV, Rogers, JE, Guinney, J, Kopetz, S, Raghav, KS. Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev). Journal of Clinical Oncology 42:201, 2024. e-Pub 2024.
10. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, participants NET. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of the National Cancer Institute 115(9):1001-1010, 2023. e-Pub 2023. PMID: 37255328.
11. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022. PMID: 35450837.
12. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
13. Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother 23(2):1-10, 2022. e-Pub 2022. PMID: 34534031.
14. Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 4(10), 2021. e-Pub 2021. PMID: 34705010.
15. Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice 17(10):607-614, 2021. e-Pub 2021. PMID: 33534616.
16. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology 11, 2021. e-Pub 2021. PMID: 34367949.
17. Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. Current oncology reports 23(4):43, 2021. e-Pub 2021. PMID: 33719003.
18. Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 33(3), 2021. e-Pub 2021. PMID: 33724586.
19. Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Therapeutic Advances in Medical Oncology 13, 2021. e-Pub 2021. PMID: 34093744.
20. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
21. Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist 21(5):563-70, 2016. e-Pub 2016. PMID: 27000464.

Professional Educational Materials

1. . Chapter on Gastrointestinal Cancers, 2022.

Other Articles

1. Dasari A, Grothey A, Kopetz S Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. J Clin Oncol 36(35):JCO2018789032. PMID: 30376428.
2. Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 19(1):e36-41, 2012. PMID: 22328846.

Editorials

1. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol 5(8):1101-1103, 2019. PMID: 31070713.
2. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol 35(3):265-267, 2017. PMID: 27893328.
3. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park) 28(9):762-3, 2014. PMID: 25224473.

Abstracts

1. Dasari A, Bent AH, Alfaro-Munoz K, Huey RW, Johnson B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian CM, Singh Raghav KP, Shen J, Willis J, Newhook TE, Uppal A, You Y, Konishi T, Chang GJ, Kopetz S, Wolff RA, INTERCEPT MD. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. Journal of Clinical Oncology 41(16):3522-3522, 2023. e-Pub 2023.
2. Smith JJ, Dasari A, Shi Q, Garcia-Aguilar J, Sanoff HK, George TJ, Hong TS, Yothers G, Philip PA, Nelson GD, Baghdadi TA, Alese OB, O'Reilly EM, Meyerhardt JA, Shergill A, Horvat N, Romesser PB, Hall WA. A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer. Journal of Clinical Oncology 41(16):TPS3640-TPS3640, 2023. e-Pub 2023.
3. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero AF, Yao JC, Garcia-Alfonso P, Kocsis J, Cubillo A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Pallai R, Carton I, Tabernero J, Eng C. Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology 41(16):3604-3604, 2023. e-Pub 2023.
4. Eng, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero AF, Yao JC, Garcia-Alfonso P, Kocsis J, Cubillo A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara FM, Schelman WR, Tabernero J. Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study. Journal of Clinical Oncology 41(16):3601-3601. e-Pub 2023.
5. Iliescu J. D-42 j Impact of Body Mass Index on Long-Term Mortality in Patients Undergoing Transcatheter Mitral Valve Replacement: A Systematic Review and MetaAnalysis. Journal of the Society for Cardiovascular Angiography & Interventions 2, 2023. e-Pub 2023.
6. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey J, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precision Oncology, 2023. e-Pub 2023.
7. Erstad, D J, Dasari, A, Taggart, M W, Kaur, H, Konishi, T, Bednarski, B K, Chang, G J. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas. Annals of surgical oncology(1-1), 2022. e-Pub 2022.
8. Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, YC Shen JP, Morelli MP, Tam A, Foo WC, Xiao L, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Journal of Clinical Oncology 40 40(4):12-12, 2022. e-Pub 2022.
9. Dasari, A, Paulson, S, Sung, M, Tucci, C, Kauh, J, Kania, M, Li, D. Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs). Paper presented at the Neuroendocrinology, 2022. e-Pub 2022.
10. Fujii, Y, Tzeng, C, Chiang, Y, Halperin, D, Dasari, A, Kim, M, Katz, M, Lee, J, Ikoma, N. Survival impact of incidence of lymph node metastases and radical resection for duodenal neuroendocrine tumors. analyses of the national cancer database, 2021. e-Pub 2021.
11. Shah, S, Gosain, R, Groman, A, Gosain, R, Dasari, A, Halfdanarson, T R, Mukherjee, S. Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the united states. Cancers, 13(8):1753, 2021. e-Pub 2021.
12. Mendis, S, Anand, S, Karasinska, J M, Dasari, A, Unger, J M, Gothwal, A, Ellis, L M, Varadhachary, G, Kopetz, S, Overman, M J. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. The Oncologist 26(2):107-114, 2021. e-Pub 2021.
13. Kunz, P, Honeycutt, H, Ward, P, Dasari, A. PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database. Value in Health 24(s64), 2021. e-Pub 2021.
14. Gouda, M, Overman, M, Huang, H, Thomas, J, Dasari, N, Meric-Bernstam, F, Kopetz, S, Janku, F. 91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer. Annals of Oncology 32:s395-s396, 2021. e-Pub 2021.
15. Kunz, P, Honeycutt, H, Ward, P, Dasari, A. PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database. Value in Health 24(2021):s64, 2021. e-Pub 2021.
16. Shah, S, Gosain, R, Groman, A, Gosain, R, Dasari, A, Halfdanarson, T, Mukherjee, S. Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States. Paper presented at the Pancreas, 2021. e-Pub 2021.
17. Dasari, N, Wang-Gillam, A, Hubbard, J, Fernandez, A, Nanda, S, Kania, M, Schelman, W, Bekaii-Saab, T. 458P Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic colorectal cancer (mCRC). Annals of Oncology 31:S436-S437, 2020. e-Pub 2020.
18. Huey R, Anand S, Rogers J, Dasari A, Varadhachary G, Gothwal A, Loree J, Ellis L, Overman M, Raghav K. Value appraisal of FDA approved cancer drugs over the past decade. J Clinical Oncology 37(27 Suppl), 2019. e-Pub 2019.
19. Wong S, Overman M, Morris V, Fogelman D, Kee B, Dasari A, Raghav K, Shureiqi I, Jian Z, Jensen-Loewe P, Wolff R, Eng C, Menter D, Kopetz S, Davis J. The association between female hormonal supplementation and molecular types in colorectal cancer. J Clinical Oncology 37(15 Suppl), 2019. e-Pub 2019.
20. Frias R, Lam M, Overman M, Morris V, Fogelman D, Kee B, Dasari A, Raghav K, Shureiqi I, Jiang Z, Jensen-Loewe P, Wolff R, Eng C, Menter D, Kopetz S, Davis J. Meat consumption and BRAF mutation status in colorectal cancer. J Clinical Oncology 37(15 Suppl), 2019. e-Pub 2019.
21. Rich T, Clifton K, Raymond V, Dasari A, Raghav K, Parseghian C, Lanman R, Kopetz S, Morris V. Association between gene fusions and anti-EGFR resistance signature in colorectal cancer. J Clinical Oncology 37(15 Suppl), 2019. e-Pub 2019.
22. Parseghian C, Willis J, Morris Van K, Raghav K, Dasari A, Raymond VM, Lanman RB, Overman M, Kopetz S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. J Clinical Oncology 37(15 Suppl), 2019. e-Pub 2019.
23. Hamilton, E, Wang, J, Li, D, Dasari, N, Paulson, S, Cohn, A, Sauter, N, Kania, M, Kauh, J, Falchook, G. Safety and tolerability of surufatinib in western patients with solid tumours. Annals of Oncology:v569-v570, 2019. e-Pub 2019.
24. Kulke, M H, Benson, A B, Dasari, A, Huynh, L, Cai, B, Totev, T, Roesner, N, Duh, M S, Neary, M P, Maurer, V E. Real‐World Treatment Patterns and Clinical Outcomes Advanced Gastrointestinal Neuroendocrine Tumors (GI NET):. A Multicenter Retrospective Chart Review Study. The Oncologist, 24(8):1056-1065, 2019. e-Pub 2019.
25. Samdani, R T, Wasylishen, A R, Halperin, D M, Dasari, A, Yao, J C, Rashid, A, Estrella, J S. Loss of Menin expression by immunohistochemistry in pancreatic neuroendocrine tumors: comparison between primary and metastatic tumors. Pancreas 48(4):510-513, 2019. e-Pub 2019.
26. Kulke, M H, Benson, A B, Dasari, A, Huynh, L, Cai, B, Totev, T, Roesner, N, Duh, M S, Neary, M P, Maurer, V E. Real‐World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET):. A Multicenter Retrospective Chart Review Study. The Oncologist 24(8):1056-1065, 2019. e-Pub 2019.
27. Halperin, D M, Lee, J J, Ng, C S, Strosberg, J R, Estrella, J S, Dagohoy, C G, Dasari, A, Yao, J C. A phase II trial of ziv-aflibercept in patients with advanced pancreatic neuroendocrine tumors. Pancreas 48(3):381-386, 2019. e-Pub 2019.
28. Dasari, A, Bergsland, E K, Benson, A B, Cai, B, Huynh, L, Totev, T, Shea, J, Duh, M S, Neary, M P, Kulke, M H. Real-world Analysis of Long-Term Treatment Patterns and Clinical Outcomes Among Patients With Advanced Neuroendocrine Tumors of Lung Origin: A Multicenter Study. Paper presented at the Pancreas, 2019. e-Pub 2019.
29. Johnson B, Loree JM, Morris VK, Dasari A, Pant S, Singh Raghav KP, Kopetz S. Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer. J Clin Oncol 37(suppl 4; abstr 596), 2019. e-Pub 2019.
30. Singh Raghav KP, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 604), 2019. e-Pub 2019.
31. Tannenbaum D, Singh Raghav KP, Horn RA, Overman MJ, Eng C, Kopetz S, Johnson B, Morris VK, Parseghian CM, Chang GJ, Rogers JE, Parker S, Angeles Lopez-Olivo MDL, Dasari A. Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. J Clin Oncol 37(suppl 4; abstr 656), 2019. e-Pub 2019.
32. Dasari, A, Joish, V, Perez-Olle, R, Dharba, S, Balaji, K, Halperin, D. PCN113 Direct and indirect costs associated with carcinoid syndrome diarrhea. Value in Health 22:s77, 2019. e-Pub 2019.
33. Adams, J, Ray, D, Willmon, R, Gautam, A, Pulgar, S, Dasari, A. Living With Neuroendocrine Tumors: Assessing Quality of Life (QoL) Through a Mobile Application. Paper presented at the Pancreas, 2019. e-Pub 2019.
34. Yeung, H, Macfarlane, A, Campbell, K, Ruth, K, Gong, Y, Engstrom, P, Dasari, A, Vijayvergia, N. Characterizing Immunophenotyping Changes with Pembrolizumab (P) Therapy in Grade 3 Neuroendocrine Neoplasms (G3 NENs). Paper presented at the Neuroendocrinology, 2019. e-Pub 2019.
35. Kulke, M H, Benson, A B, Dasari, A, Huynh, L, Cai, B, Totev, T, Roesner, N, Duh, M S, Neary, M P, Bergsland, E K. Real-world Analysis of Long-Term Treatment Patterns in Patients With Advanced Gastrointestinal Neuroendocrine Tumors (GI NET). A Multicenter Study. Paper presented at the Pancreas, 2019. e-Pub 2019.
36. Lam, M, Rogers, J, Halperin, D, Dagohoy, C, Yao, J, Dasari, A. Outcomes with 5-Fluorouracil, Doxorubicin, and Streptozocin (FAS) and subsequent therapies in patients with well differentiated Pancreatic Neuroendocrine Tumors (PanNETs. Paper presented at the Pancreas, 2019. e-Pub 2019.
37. Dasari A, Halperin D, Coya T, Zorrilla I, Meric-Bernstam F, Yao J. A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors. NANETS 2018 Symposium, 2018. e-Pub 2018.
38. Sarshekeh AM, Loree JM, Manyam GC, Pereira AAL, Raghav KPS, Lam M, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The characteristics of ARID1A mutations in colorectal cancer. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
39. Nusrat M, Oh J, Jiang ZQ, Dasari A, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
40. You YN, George TJ, Chiang YJ, Eng C, Das P, Chang GJ, Dasari A, Cuddy A, Yang Y, Yothers G. Validation Of Neoadjuvant Rectal Cancer (NAR) Score As A Surrogate Endpoint For Overall Survival In Real-life Practice Settings. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
41. Sarshekeh AM, Gu D, Zhou S, Bo Z, Shen C, Dasari A. Racial differences in the incidence and survival of patients with neuroendocrine tumors (NETs). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
42. Cruz A, Uraoka N, Cuentas ERP, Solis LM, Dasari A, Overman MJ, Loree JM, Yao JC, Wistuba II, Halperin DM, Estrella J. Prognostic significance of tumor-associated macrophages in pancreatic neuroendocrine tumors. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
43. Parseghian CM, Loree JM, Morris VK, Pereira AAL, Vilar Sanchez E, Kee BK, Raghav KPS, Dasari A, Wu J, Raymond VM, Banks K, Talasaz AA, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
44. Clifton K, Raymond VM, Dasari A, Raghav KPS, Parseghian CM, Pereira AAL, Loree JM, Yaeger R, Strickler JH, Corcoran JB, Lanman RB, Kopetz S, Morris VK. Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
45. Vijayvergia N, Dasari A, Ross EA, Dotan E, Halperin DM, Astsaturov IA, Hall MJ, Ross NM, McClean D, Denlinger CS, Cohen SJ, Engstrom PF. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
46. Huynh, L, Totev, T, Dasari, A, Bergsland, E K, Benson III, A B, Cai, B, Shea, J, Duh, M S, Neary, M P, Kulke, M H. Paper presented at the PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin: A multicenter study, 2018. e-Pub 2018.
47. Vijayvergia N, Dasari A, Ross EA, Ruth K, Litwin S, Dotan E, Halperin DM, Astsaturov IA, Hall MJ, Ross NM, McClean D, Denlinger CS, Cohen SJ, Engstrom PF. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). NANETS 2018 Symposium, 2018. e-Pub 2018.
48. Loree JM, Lam M, Morris J, Overman MJ, Raghav KPS, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Menter D, Meric-Bernstam F, Kopetz S. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. J Clin Oncol 35(suppl 4S), 2018. e-Pub 2018.
49. Sarshekeh AM, Loree J, Pereira AAL, Raghav KPS, Lam M, Advani SM, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. J Clin Oncol 36(suppl 4S), 2018. e-Pub 2018.
50. Adams J, Ray D, Willmon R, Kaleis L, Gautam A, Pulgar S, Dasari A. Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application. J Clin Oncol 36(suppl 4S), 2018. e-Pub 2018.
51. Huynh, L, Totev, T, Dasari, A, Bergsland, E K, Benson III, A B, Cai, B, Shea, J, Duh, M S, Neary, M P, Kulke, M H. Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin: A multicenter study. Paper presented at the PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018. e-Pub 2018.
52. Sarshekeh, A M, Advani, S, Halperin, D M, Conrad, C, Shen, C, Yao, J C, Dasari, A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Paper presented at the Pancreas, 2018. e-Pub 2018.
53. Prabhakar Raj N, Kelly V, Chan J A, Dasari A, Capanu M, Tang L, Reidy DL. A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin. J Clin Onc 36(suppl 4s), 2018. e-Pub 2018.
54. Dasari, A, Bergsland, E, Benson, A, Cai, B, Huynh, L, Totev, T, Shea, J, Duh, M, Neary, M, Kulke, M. Real-World Analysis of Treatment Patterns and Long-Term Effectiveness Among Patients with Advanced Neuroendocrine Tumors of Lung Origin (Lung Net). A Multicenter Study. Value in Health 21:s11, 2018. e-Pub 2018.
55. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary M, Bergsland EK. Real-world analysis of treatment patterns and persistence of octreotide LAR and other agents in patients with advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter study. J Clin Oncol 36(suppl 4S), 2018. e-Pub 2018.
56. Chun YS, Mehran RJ, Tzeng CD, Kee BK, Dasari NA, Sepsesi B, Conrad C, Aloia TA, Kopetz S, Vauthey JN. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver meastases from colorectal adenocarcinoma. J Clin Oncol, 2017. e-Pub 2017.
57. Dasari A, Shen C, Chu Y, Halperin DM, Xu Y, Zhou S, Shih T, Yao JC. Prevalence of co-morbidities in elderly patients with distant stage neuroendocrine tumors. J Clin Oncol, 2017. e-Pub 2017.
58. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Stein MN, Sanoff HK, Lee JJ, Hansen AR, Malhotra U, Rippke S, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). J Clin Oncol, 2017. e-Pub 2017.
59. Shen C, Chu Y, Dasari A, Zhou S, Halperin DM, Xu Y, Shih YT, Yao JC. Pre-existing symptoms, resource utilization, and healthcare costs prior to diagnosis of neuroendocrine tumors: A SEER-Medicare database study. J Clin Oncol, 2017. e-Pub 2017.
60. Conrad, C, Kutlu, O, Dasari, A, Lee, J. The Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas, 2017. e-Pub 2017.
61. Chun, Y S, Mehran, R J, Tzeng, C-W D, Kee, B K, Dasari, A, Sepesi, B, Conrad, C, Aloia, T A, Kopetz, S, Vauthey, J-N. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma:. American Society of Clinical Oncology, 2017. e-Pub 2017.
62. Raj, N, Chan, J, Dasari, A, Capanu, M, Tang, L, Reidy-Lagunes, D. A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of AdvancedWell Differentiated Neuroendocrine Tumors of Foregut Origin. Paper presented at the Pancreas, 2017. e-Pub 2017.
63. Dasari, A, Mehta, K, Sorbye, H, Yao, J. Gastroenteropancreatic high-grade neuroendocrine carcinomas: a SEER database analysis of 6291 cases. Paper presented at the Neuroendocrinology, 2017. e-Pub 2017.
64. Shen, C, Dasari, A, Chu, Y, Zhou, S, Halperin, D, Yao, J, Shih, Y-. Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Amng Elderly Patients. Paper presented at the Pancreas, 2017. e-Pub 2017.
65. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Shureiqui I, Kee BK, Wolff RA, Eng C, Menter D, Hamilton SR, Dasari A, Raghav KPS, Mehta TR, Manuel S, Kopetz S. Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma. J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
66. Raj N, Chan J, Dasari A, Capanu M, Tang L, Reidy-Lagunes D. A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin. NANETS 2016, 2016. e-Pub 2016.
67. Dasari A, Mehta K, Byers L, Sorbye H, Yao J. Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases. NANETS 2016, 2016. e-Pub 2016.
68. Dasari A, Shen C, Halperin D, Zhou S, Xu Y, Chu Y, Shih T, Yao J. Survival Trends in Neuroendocrine Tumors and Associated Prognostic Factors. NANETS 2016, 2016. e-Pub 2016.
69. Mehrvarz S, Advani S, Patel M, Dasari A. Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendix. ESMO 2016, 2016. e-Pub 2016.
70. Shen, C, Dasari, A, Zhao, B, Zhou, S, Halperin, D, Xu, Y. Incidence and prevalence of neuroendocrine tumors in the United States 1973–2012, 2016. e-Pub 2016.
71. Iwasaki, M, Wolin, E, Dasari, A, Liyanage, N, Lowenthal, S P, Phan, A. Response Rates with Lanreotide in the Phase III CLARINET Trial in Gastroenteropancreatic NETs (GEP-NETs), 2016. e-Pub 2016.
72. Rudek, M A, Dasari, A, Laheru, D, He, P, Jin, R, Walker, R, Taylor, G E, Jimeno, A, Donehower, R C, Hidalgo, M. Phase 1 study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. The Journal of Clinical Pharmacology 56(8):966-973, 2016. e-Pub 2016.
73. Dasari, A, Shen, C, Halperin, D, Zhou, S, Xu, Y, Chu, Y, Shih, T, Yao, J. Survival trends of neuroendocrine tumors and associated prognostic factors, 2016. e-Pub 2016.
74. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). 2016 ASCO Annual Meeting 34, 2016. e-Pub 2016.
75. Shen C, Dasari A, Zhou S, Chu Y, Xu Y, Shih YT, Yao JC, Halperin DM. Functional status of neuroendocrine tumors among elderly patients: A large population-based study using SEER-Medicare data. 2016 ASCO Annual Meeting 34, 2016. e-Pub 2016.
76. Dasari A, Halperin DM, Zhou S, Chu Y, Xu Y, Shih T, Yao JC, Shen C. Clinicopathological and demographic factors associated with development of distant metastasis among patients with locoregional neuroendocrine tumor (NET). J Clin Oncol 34, 2016. e-Pub 2016.
77. Phan AT, Dasari A, Liyanage N, Cox D, Lowenthal SP, Wolin EM. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 2016 Gastrointestinal Cancer Symposium 34, 2016. e-Pub 2016.
78. Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Singh Raghav KP, Sanchez EV, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. 2016 Gastrointestinal Cancer Symposium 34, 2016. e-Pub 2016.
79. Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Singh Raghav KP, Morris VK, Oh J, Wu J, Jiang Z, Tian F, Adam L, Brimer M, Morris J, Meric-Bernstam F, Kopetz S. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC) 34, 2016. e-Pub 2016.
80. Shen, C, Dasari, A, Zhou, S, Chu, Y, Xu, Y, Shih, Y-C T, Yao, J C, Halperin, D M. Functional status of neuroendocrine tumors among elderly patients: A large population-based study using SEER-Medicare data. American Society of Clinical Oncology, 2016. e-Pub 2016.
81. Phan, A T, Dasari, A, Liyanage, N, Cox, D, Lowenthal, S P, Wolin, E M. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs):. American Society of Clinical Oncology, 2016. e-Pub 2016.
82. Dasari A. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
83. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33, 2015. e-Pub 2015.
84. Subbiah, I M, Dasari, A, Escano, M, Dagohoy, C, Yao, J C. Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney, 2014. e-Pub 2014.
85. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting 32:5s, 2014. e-Pub 2014.
86. Hassabo HM, Sahin IH, Ali Kazmi SM, Al Mutar SS, Diniz Gomes DB, Pini TM, Sanchez EV, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Vauthey J, Hassan M, Garrett CR. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). 2014 Gastrointestinal cancer Symposium 32, 2014. e-Pub 2014.
87. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton K, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. 2014 Gastrointestinal Cancers Symposium 32, 2014. e-Pub 2014.
88. Bugano Diniz Gomes D, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off study regorafenib in patients with advanced colorectal cancer. ASCO Annual Meeting 32(3):635, 2014. e-Pub 2014.
89. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton, Manuel L, Garrett CR, Sanchez V, Pini E, Shureiqi TM, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarkers screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. GI ASCO Meeting 32(3):540, 2014. e-Pub 2014.
90. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high grade neuroendocrine carcinoma: a single institution experience. ASCO Annual Meeting 32(2):540, 2014. e-Pub 2014.
91. Dasari A, Phan A, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F Yao JC. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well differentiated neuroendocrine tumors (WD NET). 2014 ASCO Annual Meeting 32(3):232, 2014. e-Pub 2014.
92. Dasari A, Gao H, Deaton L, Overman MJ, Hauch S, Kopetz S, Reuben JM. Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. ASCO 2013 Annual Meetings, J Clin Oncol 31, 2013. e-Pub 2013.
93. Morelli, M P, Overman, M, Dasari, A, Kazmi, A, Vilar-Sanchez, E, Eng, C, Kee, B, Deaton, L, Garrett, C, Diehl, F. Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor:. American Association for Cancer Research, 2013. e-Pub 2013.
94. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. ASCO 2013 Meetings, J Clin Oncol 31, 2013. e-Pub 2013.
95. Messersmith, W, LoRusso, P, Cleary, J, Dasari, A, Huang, B, Shaik, N, Cesari, R, McLachlan, K, Kern, K, Shapiro, G. 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies. European Journal of Cancer 48:180, 2012. e-Pub 2012.
96. Lemos, R, Kopetz, S, Jiang, Z, Dasari, A, Maru, D, Powis, G. Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies. European Journal of Cancer 48:20-21, 2012. e-Pub 2012.
97. Powell RW, Tan AC, Varella-Gacia M, Touban B, Dasari A, Puls L, Pitts L, Kulikowski G, Quackenbush K, Messersmith W, Arcaroli JJ. Biomarkers for sensitivity to gamma secretase inhibitors in mouse models of pancreatic adenocarcinoma. American Association for Cancer Research, 2011. e-Pub 2011.
98. Messersmith, W, LoRusso, P, Cleary, J, Dasari, A, Zhang, X, Shaik, M, Courtney, R, Randolph, S, Shapiro, G. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 29(15):3100-3100, 2011. e-Pub 2011.
99. Dasari, A, Rudek, M, Arcaroli, J, Powell, R, Carducci, M, Laheru, D, Wright, J, Hidalgo, M, Messersmith, W, Azad, N. Tolerance of full-dose sorafenib (S) combined with irinotecan (I; weekly, two on, one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). Journal of Clinical Oncology 29(4):522-522, 2011. e-Pub 2011.
100. Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, Courtney RD, Randoulph S, Shapiro G. A Phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) w ith advanced solid tumors. ASCO Annual Meeting 29(15):3100, 2011. e-Pub 2011.
101. Powell, R W, Tan, A C, Varella-Garcia, M, Touban, B, Dasari, A, Puls, L, Pitts, T, Kulikowski, G, Quackenbush, K, Messersmith, W. Biomarkers of sensitivity to PF-03084014, a γ-secretase Inhibitor, in a preclinical model of colorectal cancer:. American Association for Cancer Research, 2011. e-Pub 2011.
102. Dasari A, Rudek MA, Arcaroli J, Powell RW, Carducci MA, Laheru D, Wright JJ, Hidalgo M, Messersmith WA. Tolerance of full-dose sorafenib (S) combined with irinotecan (i;weekly, two on one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). ASCO Annual Meeting 29(4):522, 2011. e-Pub 2011.
103. Powell RW, Messersmith W, Garcia M, Tan AC, Touban B, Pitts T, Dasari A. The combination of PF03084014 (a γ-secretase inhibitor) and Irinotecan reduces ALDH+ tumor-initiating cells and recurrence in tumors with elevated notch pathway. AACR 2010, 2010. e-Pub 2010.
104. Dasari A, Gore L, Messersmith AW, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A Phase I Safety and Tolerability Study of Vorinostat (V) in Combination with Sorafenib (S) in Patients With Advanced Solid tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase II Dose (Renal and Non-Small Cell Lung Carcinoma). ASCO Annual Meeting 2010, 2010. e-Pub 2010.
105. Dasari A, Malhotra S, spagnoletti CL. Sore Throat - Not always the usual suspect. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008. e-Pub 2008.
106. Dasari A, Malhohrta S, Spanoletti CL. A rare complication of a common disease: Pyogenic liver abscess due to diverticulitis. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008. e-Pub 2008.
107. Dasari A, Malhotra S, spagnoletti CL. Sore Throat - Not always the usual suspect. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008. e-Pub 2008.
108. Malthtra S, Lertratanakul A, Dasari A, Spagnoletti CL. An unusual cause for low back pain: Mycotic abdominal aneurysm. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008. e-Pub 2008.
109. Bartholomew, J, Dasari, A, Volonte, D, Galbiati, F. Oxidative Stress Induces Premature Senescence by Stimulating Caveolin-1 Gene Transcription through p38 MAPK/Sp 1-mediated Activation of Two GC-rich Promoter Elements, 2006. e-Pub 2006.

Book Chapters

1. Snyder, RA, Dasari, NV, You, YN. Liquid Biopsy, 457-464, 2022.
2. Dasari A, Johnson B, Parseghian P, Raghav K, Kopetz S. In: Colorectal Cancer In: The MD Anderson Manual of Medical Oncology. 4th. McGraw-hill, 2022.
3. Snyder RA, Dasari A, You Y. Liquid Biopsy. In: Colorectal Liver Metastasis, 2022.
4. Makawita S, Dasari A. In: Liquid Biopsies in Gastrointestinal Cancers In: Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer. 1st. Wolters Kluwer, 2022.
5. Das, S, Soares, HP, Dasari, NV. Neoadjuvant and adjuvant treatment strategies for well-differentiated neuroendocrine tumors, 75-86, 2021.
6. Das, S, Soares, H, Dasari, A. In: Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors Neuroendocrine Tumors, 75-86, 2021.
7. Dasari A, Das P. Could upfront chemotherapy substitute preoperative radiochemotherapy?. In: Multidisciplinary Management of Rectal Cancer - Questions and Answers, 2014.
8. Dasari A, Yao JC. Pancreatic neuroendocrine tumors. In: Textbook of Complex General Surgical Oncology. McGraw-Hill, 2014.
9. Dasari A, Messersmith WA. Colorectal Cancer. In: Clinical Decision Support System on Oncology, 2008.